[theold]

The study will examine dose, safety, tolerability, and immunogenicity of GRT-R910 at two dose levels at least four months after the second administration of their initial vaccine. GRT-R910 is also being investigated as part of a US National Institute of Health sponsored Phase 1 study.

https://economictimes.indiatimes.com/new...403132.cms



https://www.pharmaceutical-technology.co...cine-deal/